A new analytical procedure for quantifying plasma lipoproteins by proton nuclearmagnetic resonance (NMR) spectroscopy has been developed thatpotentially offers significant advantages over existing clinical methods used for assessing risk ofcoronary heart disease. Analysis of a single spectrum of a nonfasting plasma sample,acquired simplyand rapidly at moderate magneticfield strength (250 MHz), yields a completeprofile of lipoprotein concentrations: chylomicrons and very-low-, low-, and highdensitylipoproteins. The method is based on curve-fitting (spectral deconvolution) of the plasma methyllipid resonance envelope, the amplitude and shape of which depend directly on the amplitudes of the superimposed methyl resonances of the lipoprotein components. A linear least-squares curve-fitting algorithm was developed to efficiently extract the signalamplitudes(concentrations) of the lipoproteins from the plasma spectrum. These signal amplitudes correlate well with lipoprotein concentrations determined by triglyceride and cholesterol measurements.
relatively inexpensive and can be performed on blood samples from nonfasting subjects (2) . However, because an individual's true concentration of cholesterol is subject to both biological and analytical variations (3, 4) , the accurate assignment of a person's risk category requires repeated testing with carefully controlled analytical procedures (5) . Another problem unrelated to the analytical accuracy of the cholesterol assay is that substantial .numbers of individuals who have "desirable" total cholesterol values, but who are at risk for CHD because of low concentrations of HDL-C (6), will not be identified by the NCEP guidelines.
The most widely used clinical procedure for measuring LDL-C concentrations in plasma is that of Friedewald et al. (7), in which separatedeterminations of preprandial triglyceride, total cholesterol, and HDL-C are used to derive an estimateofLDL-C. Though more costly than a total cholesterol assay, the procedure is far less expensive than methods that require use of an ultracentrifuge (8) . However, reliable results can be achievedonlyforblood samplesobtainedafter at least a 12-hfast (9) , which minimizes the presence of triglyceride-rich chylomicron particles.
Another drawback is that the accuracy of the LDL-C value, the key index for clinical decision-making in the NCEP guidelines, depends on the combined reliability of the triglyceride, total cholesterol, and HDL-C measurements, all of which are subject to significant experimental error. Here we propose an alternative analytical procedure for measuring lipoproteins in plasma that potentially offers significant advantages over the standard clinical methods mentioned. In a separate study of the proton NMR characteristics of plasma from individuals with and without cancer, we demonstrated that the NMR spectrum of the plasma lipids of every person is unique and is related to lipoprotein status (10 (11, 12) . LDL-C was calculated by the method of Friedewald et al. (7) .
Lipoprotein Preparations
Fasting plasma samples were fractionated into their lipoprotein componentsby sequential flotation ultracentrifugation (13) at 4 #{176}C as previously described (10) . The following components were isolated: VLDL (<1.006 kg! L),LDL (1.006-1.063 kg/L), and HDL (1.063-1.21 kg/L).
The bottom fraction, designated "protein" (>1.21 kg/L), was also isolated. Chylomicrons (<0.940 kgfL) were isolated from the plasma samples of subjects fed a fat-rich meal,according to the procedureofHatch and Lees (14) .
The isolated components from several subjects were combined to provide stock lipoprotein solutions for preparation of simulated plasma samples and generation of the reference spectra used for curve-fitting the plasma lineshapes (spectral deconvolution).
To ensure a uniform ionic composition, which is essential for correct referencing of chemical shifts, we dialyzed each lipoprotein stock solution for 24 h at 4 #{176}C against three 1-L changes of dialysate (per liter, 120 mmol of KC1, 5 mmol of EDTA, 1 mmol of CaC12, and 1 g of NaN3, pH 7.4). Each component was then concentrated toaboutfivefold its normal plasma concentration by using a Centricon-lOmicroconcentrator (Amicon,Inc., Danvers,MA). Simulatedplasma samplesofdefined composition were preparedby combining different volumes oftheseconcentratedstock lipoprotein solutions. These samples and the stock solutions were stored at 4 #{176}C until NMR analysis. A systematic study of the effect of sample storage conditions on plasma methyl and methylene lineshape indicated that spectral changes of samples kept at 4 #{176}C were negligible for the first six days but occasionally were apparent after longer storage (notably for plasma with high concentrations of triglyceride).
NMR Spectroscopy
Before placing the samples in the spectrometer, we allowed them to equilibrate for 15- was used as previously described (10) . Each NMR sample was placed at a reproducible, defined depth in the proton probe and allowed to equilibrate for 5 mm at the chosen sample temperature (15-45 #{176}C). The probe was detuned by several megahertz to prevent radiation damping, which increased the 90#{176} pulse length from 6 to 16 ps.
Spectra were run locked with the sample spinning (20 Hz). The magnetic field homogeneity was optimized for each sample by shimming on the water signal. Reproducibly good homogeneity is important for both the quality of water suppression and the accuracy of the lineshape fitting process. This can be assured by achieving linewidths for the CaEDTA resonance in each spectrum of s3.0 Hz. Spectra were acquired with a 12-bit digitizer by using a standard one-pulse sequence preceded by a 1.0-s selective presaturation pulse at the water frequency. A spatially selective composite 90#{176} observation pulse (9O-9O-9O---9O-) was used to minimize water suppression artifacts (15) However, the methyl resonances of the lipoproteins ride on a broad, featureless signal from the protein component, which has the effect of introducing a nonlinear and somewhat variable baseline. To overcome this problem, we include in the second term of the equation boththerealand imaginary parts of the proteincomponent reference spectrum.In addition,the imaginary part of the experimental plasma spectrum isincludedas anothervariable in the thirdterm ofthe equationto correct for small, unavoidable phase differences between the plasma spectra and the lipoprotein reference spectra.
The relative lipoprotein concentrations, c, derived by this method have no absolute meaning. They relate the concentrations of the lipoprotein components of the plasma sample to those of the reference components (of arbitrarily chosen concentration) whose spectra serve as the primary standards. By referencing the signal amplitudes (integrated areas) of these primary lipoprotein standards to that of a secondary standard of well-defined proton concentration, whose spectrum is acquired under identical conditions, it is simple to convert the relative lipoprotein concentrations to units of absolute proton concentration.
In this way, direct comparisons may be made of results obtained with different instruments with use of different sets of primary standards. For a secondary standard, we used the methyl resonance of n-propanol (6.67 mmol/L in 0.5 mL of a solution of 120 mmol of KC1 and 1.2 mmol of MnSO4 per liter, pH 7.4). We included the paramagnetic ion Mn2 in the standard solution to ensure that the n-propanol methyl resonance, like the signals from the lipoproteins, would be fully relaxed under the spectral acquisition conditions used. The measured amplitude of the methyl resonance was assigned to that produced by a 20 mmol/L concentration of protons (6.67 mmolIL concentration of n-propanol x 3 protons in the methyl group). We then used this value to convert all of the NMR-derived lipoprotein concentrations to absolute proton concentration (mmoll L).
Results
The NMR spectral properties of the methyl and methylene resonances of the major lipoprotein components of plasma at 250 MHz are given in (or both) would be equally amenable to lineshape analysis. We have found, however, that the most nearly accurate results are obtained by omitting the methylene resonance entirely from consideration and using only the region of the spectrum containing the methyl resonance (see Discussion). The different positions and lineshapes of the methyl resonances of chylomicrons, VLDL, LDL, and HDL at 45 #{176}C are shown in Figure 1 . The spectral properties of these resonances at a given temperature are surprisingly invariant from person to person, despite presumed underlying differences in lipid content and lipoprotein subspecies composition (10) . This fact is key to the success of the proposed method of analysis.
Spectra obtained at different temperatures display significant variations inboth lineshape and amplitude of the methyl signals of the lipoprotein components, though the relative chemical shift differences between the components are maintained. This behavior has been welldocumented (19, 20) and is due to temperature-dependent changes in the fraction of lipoprotein lipid that exists in a fluid, NMR-detectable state. Figure 2 shows the changes in relative methyl peak amplitude observed for the four lipoprotein components over the temperature range of 15-45 #{176}C. The relative amplitudes of the signals from the triglyceride-rich chylomicrons and VLDL particles do not significantly change,in keeping with the fact that their core lipids are in a liquid-like state and do not undergo a phase transition to a more-ordered state over this range of temperatures (21) . In contrast, the amplitudes of the HDL and LDL signals increase almost two-and fivefold, respectively, primarily because of the order-disorder transition undergone by the core cholesterol esters in these lipoproteins (20) . The important consequence of this behavior, as will be discussed below, is that HDL and especially LDL make much greater contributions to the lineshape of the composite plasma methyl resonance at high temperatures than they do at lowertemperatures. Initial investigations of the feasibility of NMR lipoprotein analysis were conducted with simulated plasma samples of precisely known spectral composition. Real plasma samples were unsuitable for this purpose for two reasons. First, there is no absolute basis for comparison between NMR-derived lipoprotein concentrations (expressed as NMR signal amplitude arising from the methyl protons of the "mobile" lipids in the particles) and those determined by standard chemical means (expressed as cholesterol content). Second, there is no assurance with real plasma samples that the spectral characteristics of the lipoprotein components used in the fitting calculation are exactly identical to those of the lipoproteins in the plasma. Previous data have indicated that spectra of the lipoprotemns isolated from different people are very similar but not absolutely identical (10) . Our objective was to separate the contributions to analytical error made by the small, but finite, amount of spectral heterogeneity of the components from the "intrinsic" error of the method, e.g., from spectral noise, temperature instability, field mnhomogeneity, etc.
To accomplish this, we prepared a series of simulated fasting plasma samples by mixing defined volumes of the three pure lipoprotein components (VLDL, LDL, HDL) plus a fourth component ("protein," density >1.21 kg/L), the inclusion of which is necessary to account for the spectral contribution from the remaining heterogeneous constituents of real plasma. Because the same lipoprotein solutions were used for both the preparation of these samples and the generation of the four reference spectra used in the computer lineshape analysis, we could directly assess the "intrinsic" accuracy of the technique without the complication introduced by any small variations in lipoprotein lineshape that might exist in real plasma samples. Representative results of methyl resonance lineshape analysis of a simulated plasma sample from spectra acquired at 23 and 40 #{176}C are shown in Figure 3 . For comparison, the spectral deconvolution of an authentic plasma sample of similar lipoprotein composition is also shown. With spectra recorded at this temperature, the precision of the method is also high, as seen by the low standard deviations observed for analyses of duplicate spectra of each sample. The average CVs calculated for VLDL, LDL, and HDL from the 40#{176}C data set in Table 2 were 3.1%, 2.3%, and 1.4%,respectively. At 23 #{176}C, both the accuracy and the precision of the results were considerably less, especially for LDL. The reason for this can be understood by notingthat at 23 #{176}C the broad,featureless signal from the LDL component (Figure 3 ) makes a relatively small contribution to the overall plasma lineshape because most of its core lipid is in an ordered, NMR-undetectable state (see Figure 2 ). In the authentic serum at 40 #{176}C ( Figure 3 ) the relative amplitudes of the LDL and HDL signals much more closely approximate the relative amounts of LDL-and HDL-C in the sample.
Having demonstrated that at warmer temperatures simulated plasma could be accurately and precisely analyzed by fitting the methyl lipid resonance, we proceeded to analyze the 40 #{176}C spectra of several authentic fasting plasma samples, using the same four reference lipoprotemn spectra as in the simulated plasma study. In general, we obtained excellent fits between experimentaland calculated spectra, which indicates that the influence of lipoprotemn lineshape heterogeneity among individuals is not large. Better and more direct evidence for this conclusion comes from the good correlations found between the lipoprotein signal amplitudes derived indirectly by plasma lineshape analysis and those measured directly from determinations of the integrated areas of the signals obtained from the isolated lipoprotein components of these samples ( Figure  4 ). The small amount of scatter in these regression plots is considered at least as likely to arise Figure 1 , the methyl resonance lineshape of chylomicrons is very similar to that of VLDL, but the signal is shifted slightly downfield. To determine the effect of the presence of high concentrations of chylomicrons on the quantification of VLDL, LDL, and HDL by lineshape fitting, we analyzed by NMR and chemical methods fasting and nonfasting plasma samples from individuals fed a fat-rich meal. The spectra and lineshape fits of the sample containing the highest concentration of chylomicrons are shown in Figure 6 . The presence of chylomicrons in the postprandial sample is easily discerned by the altered position of the plasma peak maximum.
By including chylomicrons as a fifth component in the lineshapeanalysis, we not only obtainedan excellent fit oftheexperimental plasma spectrum ( Figure 6 ), but alsofound the derivedconcentrations of VLDL, LDL, and HDL to be nearly identical to those in the fasting state (Table 3 ). These and similar results obtained for other postprandial samplesindicate that lipoprotems can be reliably analyzed in nonfasting plasma by NMR. In contrast, thewidelyused method of Friedewald et al. (7) has an absolute requirement for fasting samples because the accuracy of LDL-C values is severely compromised by the presence of chylomicrons.
Discussion
The procedure presented here for quantifying lipoproteins by proton NMR spectroscopy is a fundamental departure from standard clinical methods of analysis or iinmunochemical means to quantify specific lipid or apolipoprotein constituents of the lipoproteins.
Instead of measuring a discrete chemical entity, the NMR method measuresthe amplitude of the proton NMR signal produced by the lipoprotein under a defined set of conditions. This approach has many potential advantages but also raises important questions regarding the exactnatureofthe information provided by lipoprotein signal amplitudes, the relationships that exist between NMR signal amplitude and lipoprotein lipid composition and particle con- The dashed verticallinefacilitatescomparisonsofchemicalshifts betweenthe top and bottom spectra. The vertical scaling of the spectra of the fasting sample is 70% greater(xl .7) than that of the postprandialsample centration, and the clinical utility of NMR-derived lipoprotein concentrations.
The benefits offered by the NMR lipoprotein assay can best be explained by comparison with existing analytical methods of lipoprotein lipid determination. These all have in common the use of a comparison procedure to relate an experimental observation (usually absorbance) to known concentrations of the chemical constituent being analyzed. In laboratories using automated procedures, these measurements are generally performed with good precision(reproducibility) but less than desirable accuracy (agreement with the true value) (4). Contributing to this problem are matrix effects (differential analytical responses from patients' and "reference" samples, arising from differences in the physical environment of the analyte) and method-specific biases exhibited by the many different methodinstrument combinations in clinical use. To some extent, these sources of interlaboratory variability can be minimized by adopting more-uniform standardization practices, and a national campaign to accomplish this goal has recently been initiated by the NCEP (5) . Even if the campaign is successful, the need for accurate measurement of LDL, the causal lipoprotein for CHD and the risk factor assigned the most weight in the NCEP guidelines (1) , is expected to pose a continuing challenge.There currently being no cost-effective method to measure LDL directly, this concentration (expressed in terms of cholesterol content) must be determined indirectly by the Friedewald formula (7) from the concentrations of plasma triglyceride, total cholesterol, and HDL cholesterol. This procedure not only places a high premium on the accuracy of three separate lipid determinations, but also requires a fasting plasma specimen.
The proposed NMR method of lipoprotein analysis offers several potential advantages. Foremost is that a complete lipoprotein profile is produced by a single, direct measurement. The profile includes the concentrations of not only HDL and LDL, but also VLDL, a lipoprotein that has heretofore been difficult to quantify and may have independent value for assessing CHD risk (22) . Another advantage of practical importance is that, unlike the method of Friedewald et al. (7) , the NMR lipoprotein assay can apparently be used reliably with nonfasting plasma samples. Although this conclusion will need to be verified with a more comprehensive study of pre-and postprandial specimens, our preliminary results ( Figure 6, Table 3 ) indicate that even very high chylomicron concentrations do not significantly impair accurate quantification of HDL and LDL.
If the cost of the NMR lipoprotein assay could be made competitivewith that of plasma cholesterol, its use would become an attractive alternative to the current two-tiered practice of assigning CHD risk by initial classification according to total cholesterol, followed (if indicated) by classification based on LDL-C (1) . A major determinant of the ultimate cost of NMR lipoprotein analysis will be the magnetic field strength required to produce reliable results. Again, a systematic study of this variable is needed, but our results indicate that the measurement can be performed accurately with an intermediate-field spectrometer (250 MHz). Additional cost efficiency should result from the fact that the test requires no reagents and no sample manipulation beyond separation of the blood into plasma. The entire procedure-acquiring the plasma NMR spectrum and performing the computer lineshape analysis-could easily be automated, such that samples could be analyzed at a rate of about one per minute. Proper design of such an automated instrument should minimize or eliminate experimental variables that adversely affect analytical precision and accuracy (i.e., sample temperature, magnetic field, and radiofrequency homogeneity). That would leave inherent detection sensitivity (NMR signal amplitudegeneratedper pulse) as the only significant remaining source of day-to-day or interlaboratory variability. Because differences in detection sensitivity can be simply and accurately quantified by periodic measurement of the spectrum of an agreed-upon secondary standard (such as the n-propanol standard we used here), it should be possible toachieveexcellent interlaboratory agreement by normalizing the measured amplitude of the plasma methyl resonance to that of the standard.
Turning now to issues related to the underlying basis of the NMR assay and the accuracy with which NMRderived lipoprotein concentrations can be determined, it is important to understand the potential influences of lipoprotein heterogeneity. The feasibility of NMR lipoproteinanalysis rests entirely on the assumption that plasma consists of a discrete number of spectrally distinct components, the spectral properties of which (lineshape and chemical shift) are invariant from person to person. However, each of the major classes of lipoproteins contains subspecies exhibiting a range of particle diameters, buoyant densities, and lipid compositions (23) . Although one might anticipate that dietary influences or variations in the relative concentrations of the subspecies would lead to unacceptable lineshape variability of the components, we have accumulated a substantial body of data indicating that this is not the case. Some minor differences in lineshape are sometimes observed for different samples of the same lipoprotein component, but these are very small compared with the spectral differences between the component classes. Thus, despite underlying compositional heterogeneity, the major density classes of lipoproteins (chylomicrons, VLDL, LDL, HDL) operationally satisfy the essential criterion of spectral homogeneity.
At the present stage of development, no provision has been incorporated in the lineshape analysis algorithm to adjust for small discrepancies between the spectral properties of the lipoprotein components of the plasma sample being analyzed and those of the "standard" lipoprotein spectra used in the computer fit. These discrepancies are a direct source of analytical error, which we estimate can lead in unfavorable cases to differences of as much as 10% between calculated and true lipoprotein concentrations. By reaching a better understanding of the origins and extent of lipoprotein spectral variability, we believe it should be possible to devise optimization routines that not only improve analytical accuracy, but also possibly supply information regarding lipoprotein subspecies and (or) lipid composition that could otherwise be obtained only by far more time-consuming and labor-intensive methods.
The requirement for lipoprotein spectral homogeneity was also one of the main factors that led to our decision to use the methyl, rather than methylene, lipid resonance for lineshape analysis. As indicated in Table 1 , both the methyl and methylene signals exhibit lipoprotein chemical shift differences of similar magnitude. However, the methyl resonances of LDL and HDL are substantially narrower than the corresponding methylene resonances. At higher magnetic field strengths, where the effects of underlying chemical shift heterogeneity are accentuated, these linewidth differences are even more pronounced and the methyl resonance lineshapes exhibit far less person-to-person variability than do the methylene resonances (10) . Both of these observations are consistent with the more uniform microenvironments of the methyl protons of the lipoprotein lipids, given their location at the ends of the fatty acyl chains. By contrast, the protons contributing to the methylene resonances are located in more heterogeneous environments and can be differentially influenced by fatty acid composition (number and locations of sites of unsaturation) and lipid-packing interactions. Another reason to focus on the plasma methyl resonance is that its lineshape is less susceptible than that of the methylene resonance to being dominated by its chylomicron and VLDL components, which have high CH2/ CH3 signal amplitude ratios. This is especially important when attempting to quantify LDL and HDL concentrations in triglyceride-rich nonfasting plasma samples. Finally, by choosing to omit the methylene resonance from consideration, we completely avoid the problems caused by the presence in this spectral region of interfering resonances from nonlipid metabolites such as lactate, threonine, hydroxybutyrate, and valine (24) .
The last issue we discuss is the meaning of NMRderived lipoprotein concentrations and their relationship to lipoprotein concentrations measured by other methods. Historically, the different classes of lipoproteins were separated by ultracentrifugation and quantilled by refractometric methods in an analytical ultracentrifuge (25) . Later, it became much more convenient to measure lipoprotein concentrations in terms of cholesterol content rather than total mass, and almost all clinical and epidemiologic studies of heart disease risk have therefore focused on associations with the concentrations of lipoprotein cholesterol. However, lipoprotein cholesterol concentrations do not provide a true measure of lipoprotein particle concentrations because lipoproteins have somewhat variable lipid compositions. A better measure of lipoprotein particle concentration may be provided by the concentrations of certain apolipoproteins, some of which have been claimed to be better discriminators for assessing CHD risk, possibly for that reason (26) .
As noted earlier, lipoprotein concentration determined by NMR spectral analysis is defined in yet another way, namely, as the amplitude of NMR signal produced under a given set of conditions by a particular concentration of lipoprotein. There are two somewhat disconcerting and perhaps confusing aspects to measuring lipoproteins in this manner. First, the NMR signal does not originate from a single chemical species such as cholesterol. Instead, it arises from whatever mix of lipids happens to be in a fluid, NMR-detectable state under the conditions of the measurement (19, 20) . Second, the amount of lipid in the disordered, NMR-detectable state is a sensitive function of temperature and is known to be influenced to various extents by factors such as lipid composition (triglyceride/cholesterol ester ratio), fatty acid composition (unsaturatedlsaturated fat ratio), and lipid-packing constraints (particle diameter) (19) (20) (21) . The temperature dependence of lipoprotein signal amplitude near physiological temperatures is particularly strong for LDL, less strong for HDL, and almost nonexistent for VLDL and chylomicrons ( Figure   2 ).
Because of the potential influence of so many factors besides lipoprotein particle concentration on NMR signal amplitude, it might seem unrealistic to expect a close correspondence between NMR-derived concentrations of lipoproteins and those measured by other method.s.However, if the temperature of the measurement is appropriately chosen and experimental conditions are carefully controlled, we find this not to be the case. If the plasma spectrum is acquired at a relatively high temperature (above the lipid order-disorder phase transitions), most of the lipid in the lipoproteins is detectable by NMR. Under these conditions, lipoprotein signal amplitudes should correlate well with particle concentration and be influenced relatively little by lipid or subspecies compositional differences. We have found that 45 #{176}C is the highest temperature at which the NMR measurement can be reliably performed without encountering problems of protein denaturation. As shown in Figure 5 , NMR-derived lipoprotein concentrations obtained from spectra acquired at 45 #{176}C indeed correspond well with lipoprotein cholesterol concentrations. The correlation is better for HDL (r = 0.912) than for LDL (r = 0.801), but the significance of this difference cannot be assessed without knowing the magnitude of the separate contributions made to analytical error by the NMR and the lipoprotein cholesterol measurements. Studies to address this question are in progress. At lower measurement temperatures, near or below the lipid phase transitions, lipoprotein signal amplitudes may be expected to embody information regarding both particle concentration and composition. A possible method of extracting this information (at the cost of increased measurement time) is to acquire the plasma spectrum at two temperatures, one near and one above the phase transition(s).
The ratio of lipoprotein signal amplitude at the two temperatures (extracted by lineshape deconvolution) might then permit the respective contributions of particle concentration and lipid or subspecies composition to be evaluated. Because of some evidence of associations between lipoprotein composition and heart disease (23) , such temperature-dependent data might have independent diagnostic utility for CHD risk assessment.
In summary, the results presented here, although preliminary, are highly supportive of the feasibility of deriving complete lipoprotein profiles from easily obtainable proton NMR spectra of blood plasma. This method appears to offer significant advantages over existing screening procedures for CHD risk, although many questions remain to be answered regarding its potential limitations and the nature and utility of the information it provides. Although NMR is not generally used as a clinical analytical tool, nor is it usually thought of as such, our results indicate that it may be well suited for plasma lipoprotein analysis. 
